Pharmaceutical Import Rules

The United States applies zero tariffs on most finished pharmaceutical imports under Most Favored Nation (MFN) trade rules — drug pricing is fundamentally a domestic policy problem, not a customs problem. What the federal government tightly restricts is the importation of drugs that haven't cleared FDA approval: under 21 U.S.C. § 381, FDA can refuse entry to any drug that appears adulterated, misbranded, or otherwise noncompliant with U.S. standards. This means that buying drugs from Canadian pharmacies — even identical, FDA-approved medications manufactured in the same plants — is technically illegal under the Federal Food, Drug, and Cosmetic Act. In practice, the FDA exercises enforcement discretion for personal importation: consumers who purchase a 90-day personal supply of a drug they're already taking, for their own use, are generally not pursued. Several states have implemented Canadian importation programs under a 2020 FDA rule, but implementation has been limited. The real drug pricing debate is domestic — Medicare negotiation under the Inflation Reduction Act, pharmacy benefit manager (PBM) regulation, biosimilar competition — not tariffs, though Trump administration proposals in 2025 to impose tariffs on pharmaceutical imports added a new dimension to the policy landscape.

Current Law (2026)

U.S. pharmaceutical import policy restricts importation of prescription drugs while maintaining relatively low tariffs on pharmaceutical ingredients. Drug pricing is primarily a domestic regulatory and market issue rather than a tariff issue.

Parameter	Value
Tariff on finished pharmaceuticals	Generally 0% (MFN)
Personal importation	Technically illegal, but FDA exercises enforcement discretion for 90-day supply
Canadian importation (state programs)	Legal under certain conditions (limited implementation)
Biosimilar competition	Growing, saving estimated $100B+ over next decade

Legal Authority

21 U.S.C. § 331 — Prohibited acts under the Federal Food, Drug, and Cosmetic Act (includes prohibition on importation of unapproved, adulterated, or misbranded drugs)
21 U.S.C. § 381 — Imports and exports (FDCA) (Secretary may refuse admission of any drug that appears to be adulterated, misbranded, or not in compliance with FDA requirements)
21 U.S.C. § 384 — Importation of prescription drugs (authorizes state wholesale importation programs from Canada subject to HHS certification of safety and cost savings; personal importation enforcement discretion)
Importation of Prescription Drugs Act (within ACA/state programs) — Limited Canadian importation
FDA Safety and Innovation Act — Drug supply chain security

How It Works

Under 21 U.S.C. § 381, the FDA can refuse entry to any imported drug that appears adulterated, misbranded, or noncompliant with U.S. standards — which means importing prescription drugs from foreign pharmacies, including Canadian ones selling identical FDA-approved medications, is technically illegal under the Federal Food, Drug, and Cosmetic Act. In practice, the FDA exercises enforcement discretion for personal importation: individuals who purchase a 90-day personal supply of a drug they're already taking, for their own use only, from a pharmacy in a country with comparable safety standards, are generally not pursued. This is a policy, not a legal right, and it doesn't cover controlled substances, biologics, or commercial quantities.

Congress created a formal pathway for state-level importation programs under 21 U.S.C. § 384: states can establish programs to import prescription drugs from Canada in bulk, subject to HHS certification that the program is safe and will produce cost savings. The Trump FDA approved Florida's program in 2025, along with programs from Texas, Tennessee, and Colorado — the first state programs approved under this authority. Canada has objected, arguing the exports will deplete Canadian drug supplies, and litigation from pharmaceutical manufacturers challenging the programs is ongoing. Even if implemented fully, state importation programs address a narrow slice of drug spending compared to the broader domestic pricing policy levers: the IRA's Medicare negotiation program (see Medicare Drug Price Negotiation) and growing biosimilar competition under the Biologics Price Competition and Innovation Act (BPCIA) pathway.

The drug supply chain adds another layer of complexity: approximately 80% of Active Pharmaceutical Ingredients (APIs) used in U.S. drugs are manufactured in China and India. The finished drug may face import restrictions, but the raw materials are deeply global — and tariffs on Chinese imports raise API input costs, which flow through to generic drug prices. This is an underappreciated consequence of trade policy for healthcare costs, distinct from the retail import restriction question.

How It Affects You

If you're paying high prices for brand-name drugs: U.S. prescription drug prices are 2-5x higher than Canada, Germany, or the UK for the same drugs — the import restriction is one of several legal mechanisms maintaining this differential. For personal purchases, FDA exercises enforcement discretion for a 90-day supply imported for personal use from a foreign pharmacy — meaning the agency generally will not take action against individuals bringing medications across the border from Canada or Mexico, or ordering from reputable international online pharmacies, as long as the drug is for personal use, not controlled substance, not a biological, and not a commercial quantity. Mark Cuban's Cost Plus Drugs (costplusdrugs.com) is a domestic alternative worth checking — it offers generic drugs at manufacturing cost plus a small margin, with prices frequently 80-90% below retail. For biologics like Humira (adalimumab), biosimilar competition has begun driving down prices from $6,600/month for the brand to under $2,000 for multiple approved biosimilars — if you're paying brand prices for a biologic, ask your pharmacist or doctor whether an interchangeable biosimilar is available.

If you're considering ordering drugs from Canada or another country online: The FDA's enforcement discretion is real but conditional — it's a policy, not a legal right. The agency can and does seize shipments that don't meet its criteria (commercial quantities, controlled substances, unapproved biologics, or drugs from countries without adequate safety standards). The bigger risk from unregulated international pharmacy websites is counterfeit or substandard drugs. Look for pharmacies verified through the National Association of Boards of Pharmacy (NABP) — their VIPPS program (Verified Internet Pharmacy Practice Sites) and DotPharmacy domain certification identify legitimate pharmacies. Canadian provincial licensing boards publish authorized pharmacy lists. Avoid any online pharmacy that: offers drugs without a valid prescription, isn't licensed in a U.S. state or Canadian province, or sells drugs at prices too good to be true. Counterfeit insulin, blood pressure medications, and cancer drugs have all been identified in unregulated online pharmacy supply chains.

If you're a Medicare Part D beneficiary: The IRA's Medicare drug price negotiation program — the first time Medicare has been allowed to directly negotiate drug prices — selected its first 10 drugs in 2023, with negotiated prices effective for 2026. The program covers high-cost drugs like Eliquis, Jardiance, Xarelto, and others with the highest Medicare spending. The IRA also capped Medicare Part D out-of-pocket spending at $2,000 per year starting in 2025 (down from effectively unlimited under prior law) — one of the most significant drug pricing changes for Medicare beneficiaries in decades. Biosimilar uptake under Medicare Part D has accelerated; CMS now incentivizes prescribing of interchangeable biosimilars. Check your plan's formulary annually during open enrollment — biosimilar availability has shifted tier placement for many brand drugs.

If you're monitoring pharmaceutical supply chain vulnerability: Approximately 80% of Active Pharmaceutical Ingredients (APIs) used in U.S. drugs are manufactured in China and India. The COVID-19 pandemic (2020-2021) disrupted API supply chains and created shortages of generic drugs including generic antibiotics and sedatives. Congress passed the BIOSECURE Act (targeting specific Chinese biotech companies with U.S. government contracts) and DOD has invested in domestic API manufacturing through defense supply chain resilience programs. Trump-era tariffs on Chinese goods raised API input costs, which flows through to generic drug prices — an underappreciated consequence of trade policy for healthcare costs. FDA's Drug Shortage Staff tracks active shortages at accessdata.fda.gov; the current list typically includes 100-200 drugs at any given time.

State Variations

FL: First state with HHS-approved Canadian importation program (implementation pending litigation)
CO, ME, NH, NM, VT: Have enacted Canadian importation laws, awaiting or seeking HHS approval
State pricing transparency: Multiple states have enacted drug price transparency laws requiring manufacturers to justify price increases

Implementing Regulations

21 CFR Parts 200–299 — FDA drug regulations (drug manufacturing, labeling, distribution, import requirements, personal importation policy)
19 CFR Part 12 — CBP special classes of merchandise (imported drug inspection and detention)

Pending Legislation (119th Congress)

HR 3375 (Rep. Van Drew, R-NJ) — Fair Prescription Drug Prices for Americans Act. Would cap U.S. drug list prices to the average of six countries, require annual price reporting, and impose per-unit penalties. Status: Introduced.
S 1587 (Sen. Hawley, R-MO) — Fair Prescription Drug Prices for Americans Act. Would cap U.S. retail drug and biologic list prices to the average in six countries. Status: Introduced.
S 1818 — Prescription Drug Price Relief Act of 2025. Would force HHS reviews of brand drug prices, void exclusivities for excessive prices, and open licensing with royalties. Status: Introduced.
HR 3493 (Rep. Khanna, D-CA) — Global Fairness in Drug Pricing Act. Would tie U.S. drug prices to international benchmarks, allow selective importation, and boost antitrust scrutiny. Status: Introduced.
HR 7391 — Community Health Center Drug Pricing Protection Act. Would bar deals that make community health centers pay above the 340B price at purchase. Status: Introduced.
HR 3162 (Rep. Schakowsky, D-IL) — Affordable and Safe Prescription Drug Importation Act of 2025. Allows federal importation of certain prescription drugs from trusted countries to lower costs. Status: Introduced.
HR 3546 (Rep. Khanna, D-CA) — Prescription Drug Price Relief Act of 2025. Would let the government override drug exclusivities when U.S. prices exceed global benchmarks. Status: Introduced.

Recent Developments

The FDA announced availability of revised draft guidance in March 2026 on biosimilar development under the Biologics Price Competition and Innovation Act (BPCI Act), addressing new and revised Q&As for manufacturers seeking approval of biosimilar biological products.

Trump state drug importation programs approved (2025): The FDA approved Florida's Section 804 importation program — the first state drug importation program approved under the federal importation authority — allowing Florida to import prescription drugs from Canada. The Trump FDA, reversing Biden-era hesitancy, approved additional state programs in Texas, Tennessee, and Colorado. The programs allow state health agencies to bulk-import approved drugs from Canadian wholesalers at Canadian prices (typically 30-80% below U.S. prices). Canada has objected to the programs, arguing the exports will deplete Canadian drug supplies; U.S.-Canada tensions over the importation programs remain unresolved.
Most Favored Nation Executive Order: Trump signed an executive order in May 2025 directing HHS to establish a "most favored nation" (MFN) pricing mechanism — tying Medicare drug prices to the lowest price paid by peer nations (Germany, Japan, UK, France, Canada). The EO directed CMS to develop an MFN payment model through the CMS Innovation Center. Drug manufacturers and pharmacy benefit managers challenged the EO as exceeding executive authority; litigation is ongoing. A similar MFN model proposed by Trump in his first term was vacated by a federal court in 2021 for failing to go through notice-and-comment rulemaking. The current EO attempts to use CMMI's broader innovation authority to avoid the APA challenge.
Tariffs on pharmaceutical imports — carve-out debate: Trump's broad import tariffs (10% baseline, with higher rates on China and other countries) created uncertainty for pharmaceutical manufacturers with global supply chains. Initial tariff orders included a carve-out for pharmaceutical products; the administration has deliberated whether to apply tariffs to finished drugs and active pharmaceutical ingredients (APIs), most of which are manufactured in China and India. Imposing tariffs on APIs would significantly increase U.S. drug production costs — a tension with the goal of reducing drug prices. The pharmaceutical industry has pushed for Section 232 national security tariff exemptions for medications and APIs.
Generic drug supply chain resilience: COVID-19 exposed the vulnerability of U.S. generic drug supply chains — over 90% of generic APIs are manufactured in China and India. The FDA's Drug Shortages Task Force and the OBBBA's "Buy American" pharmaceutical provisions directed FDA and HHS to develop a domestic API manufacturing strategy. The BARDA (Biomedical Advanced Research and Development Authority) has funded domestic API manufacturing pilot programs, but building domestic generic API capacity faces significant cost disadvantages versus Asian manufacturers. The Essential Medicines Act (proposed in multiple Congresses) would mandate domestic sourcing for a list of critical generic medications; it has not yet passed.